Montserrat A, Taruscio D. Policies and actions to tackle rare diseases at European level. Ann Ist Super Sanita. 2019; 55(3): 296-304.

Berry SA, Coughlin ll CR, McCandless S, McCarter R, Seminara J, Yudkoff M, et al. Developing interactions with industry in rare diseases: lessons learned and continuing challenges. Genetics in Medicine. 2020; 22 (1): 219-226.

Löblová O, Csanádi M, Ozieranski P, Kaló Z, King L, McKee M. Alternative access schemes for pharmaceuticals in Europe: towards an emerging typology. Health Policy. 2019; 123(7): 630-634.

Vicente E, Guevara M, Lasanta MJ, Ramos-Arroyo MA, Ardanaz E.Red Española de Registros de Enfermedades Raras para la Investigación: primeros resultados del proyecto Spain-RDR en Navarra. An Sist Sanit Navar. 2019; 42(2): 179-186.

Zamora B, Maignen F, O’Neill P, Mestre-Ferrándiz J, Garau M. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019; 14(1): 95.